DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Everence Capital Management Inc.

Everence Capital Management Inc. trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 43.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,530 shares of the medical device company's stock after selling 8,940 shares during the quarter. Everence Capital Management Inc.'s holdings in DexCom were worth $897,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Sachetta LLC increased its stake in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after acquiring an additional 171 shares during the period. Versant Capital Management Inc purchased a new stake in DexCom in the 4th quarter valued at approximately $25,000. Riverview Trust Co increased its position in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares during the period. RPg Family Wealth Advisory LLC purchased a new position in shares of DexCom during the 3rd quarter worth approximately $57,000. Finally, Covestor Ltd lifted its holdings in shares of DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company's stock valued at $64,000 after buying an additional 335 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Up 3.3 %

Shares of DexCom stock traded up $2.57 during mid-day trading on Friday, hitting $81.07. 2,684,354 shares of the stock were exchanged, compared to its average volume of 2,464,127. The stock has a market capitalization of $31.67 billion, a price-to-earnings ratio of 48.55, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a 50-day simple moving average of $76.12 and a 200 day simple moving average of $80.29.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DXCM shares. StockNews.com lowered DexCom from a "buy" rating to a "hold" rating in a report on Saturday, November 2nd. Leerink Partners lowered their price target on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Citigroup boosted their price objective on shares of DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Oppenheimer dropped their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Finally, Raymond James decreased their price target on DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $98.00.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.30% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.